PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Marianne Davies , DNP, ACNP, AOCNP - Maximizing the Benefits and Minimizing the Risks of Cancer Immunotherapies in Everyday Oncology Practice: Need-to-Know Information and Practical Guidance for Oncology Nurses
Go online to PeerView.com/WUA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an oncology nurse practitioner and expert in immuno-oncology provides a comprehensive overview of cancer immunotherapies, including how the immune checkpoint inhibitors work, their efficacy and safety profiles, and the latest approvals and indications. In addition, practical guidance for determining candidates for immune checkpoint inhibitor therapy, recognizing and managing immune-related adverse effects, and educating and counseling patients and survivors about this new class of agents and what to expect during and after treatment is offered. Upon completion of this activity, participants will be able to: Assess clinical data on the efficacy and safety of cancer immunotherapies and immune-based combinations across the oncologic spectrum, Describe indications for and roles of immunotherapies and combinations in the treatment of different cancers, Discuss factors that should be considered in determining best candidates for cancer immunotherapies, including patient-related factors and predictive biomarkers, Characterize potential immune-related adverse effects (irAEs) of cancer immunotherapies and how to recognize, diagnose, and manage them, Evaluate patients with cancer to help determine who would/would not be good candidates for cancer immunotherapy, Manage irAEs according to the latest recommendations and best practices, Educate patients with cancer and survivors about the basics of immuno-oncology, what to expect during and after treatment with cancer immunotherapies, and how they can collaborate with their nurses, nurse navigators, other members of the oncology team, and other providers to maximize the benefits and minimize the risks of these therapies